Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs
Provided By PR Newswire
Last update: Feb 25, 2025
HONG KONG, Feb. 24, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that its partner on ivonescimab, Summit Therapeutics Inc. (NASDAQ: SMMT) has entered into a clinical trial collaboration with Pfizer Inc. (NYSE: PFE) to evaluate ivonescimab, a novel, investigational PD-1 / VEGF bispecific antibody, in combination with several of Pfizer's antibody drug conjugates (ADCs) across multiple solid tumor settings.
Read more at prnewswire.com27.9
+3.23 (+13.09%)
24.2
+0.27 (+1.13%)
Find more stocks in the Stock Screener
SMMT Latest News and Analysis
8 days ago - ChartmillLet's have a look at the top gainers and losers one hour before the close of the markets of today's session.Intrigued by the market activity one hour before the close of the markets on Friday? Uncover the key winners and losers of today's session in our insightful analysis.
9 days ago - ChartmillTop stock movements in today's session.Stay up-to-date with the latest market trends in the middle of the day on Friday. Explore the top gainers and losers during today's session in our detailed report.
